- Report
- July 2024
- 174 Pages
Global
From €3980EUR$4,500USD£3,436GBP
- Report
- August 2022
- 113 Pages
Global
From €3980EUR$4,500USD£3,436GBP
- Report
- January 2024
- 120 Pages
Global
From €3500EUR$4,240USD£3,128GBP
- Report
- October 2023
- 127 Pages
Global
From €3500EUR$4,240USD£3,128GBP
- Report
- October 2023
- 126 Pages
Global
From €3500EUR$4,240USD£3,128GBP
- Report
- April 2024
- 107 Pages
Global
From €3500EUR$4,240USD£3,128GBP
- Report
- October 2023
- 115 Pages
Global
From €3500EUR$4,240USD£3,128GBP
- Report
- July 2023
- 87 Pages
Global
From €3500EUR$4,240USD£3,128GBP
The Fetal Bovine Serum (FBS) market is a subset of the biotechnology industry. FBS is a type of serum derived from the blood of unborn calves. It is used in a variety of research and medical applications, such as cell culture, tissue engineering, and drug development. FBS is a valuable resource for scientists and medical professionals, as it contains a variety of growth factors and nutrients that are essential for cell growth and development.
FBS is a highly regulated product, and its production is subject to strict quality control standards. As a result, the FBS market is highly competitive, with a number of companies offering a variety of products. Companies in the FBS market include Sigma-Aldrich, Thermo Fisher Scientific, Merck KGaA, and Bio-Techne. Show Less Read more